Luminex (LMNX) Earns “Market Perform” Rating from William Blair

Luminex (NASDAQ:LMNX)‘s stock had its “market perform” rating reissued by stock analysts at William Blair in a research note issued on Tuesday.

LMNX has been the topic of a number of other research reports. BidaskClub cut Luminex from a “sell” rating to a “strong sell” rating in a research note on Wednesday, December 27th. BTIG Research began coverage on Luminex in a research note on Friday, January 5th. They issued a “buy” rating and a $24.00 price target on the stock. TheStreet raised Luminex from a “c+” rating to a “b-” rating in a research note on Wednesday, November 1st. Finally, Jefferies Group reissued a “hold” rating and issued a $21.00 price target on shares of Luminex in a research note on Friday, October 20th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $22.33.

Shares of Luminex (NASDAQ LMNX) opened at $19.31 on Tuesday. Luminex has a 1 year low of $17.68 and a 1 year high of $22.42. The company has a market cap of $839.68, a PE ratio of 29.26, a price-to-earnings-growth ratio of 1.82 and a beta of 0.13.

Luminex (NASDAQ:LMNX) last issued its quarterly earnings results on Monday, February 12th. The medical instruments supplier reported $0.20 EPS for the quarter, topping the consensus estimate of $0.09 by $0.11. Luminex had a net margin of 9.52% and a return on equity of 6.01%. The firm had revenue of $78.20 million for the quarter, compared to analysts’ expectations of $77.33 million. During the same period in the previous year, the business earned $0.11 earnings per share. Luminex’s revenue for the quarter was up 8.2% compared to the same quarter last year. sell-side analysts expect that Luminex will post 0.49 EPS for the current fiscal year.

In other Luminex news, Director G Walter Loewenbaum II sold 50,000 shares of Luminex stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $21.79, for a total transaction of $1,089,500.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders sold a total of 131,698 shares of company stock worth $2,761,201 in the last three months. 6.90% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the business. First Quadrant L P CA purchased a new position in Luminex during the 3rd quarter valued at about $173,000. Creative Planning purchased a new position in Luminex during the 4th quarter valued at about $198,000. UBS Asset Management Americas Inc. purchased a new position in Luminex during the 4th quarter valued at about $206,000. Crossmark Global Holdings Inc. purchased a new position in Luminex during the 3rd quarter valued at about $254,000. Finally, Teacher Retirement System of Texas purchased a new position in Luminex during the 4th quarter valued at about $270,000. 76.64% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This report was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/02/13/luminex-lmnx-earns-market-perform-rating-from-william-blair.html.

Luminex Company Profile

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply